Generic Auryxia Availability

Last updated on Jun 11, 2025.

Auryxia is a brand name of ferric citrate, approved by the FDA in the following formulation(s):

AURYXIA (ferric citrate - tablet;oral)

• Manufacturer: KERYX BIOPHARMS
  Approval date: September 5, 2014
  Strength(s): EQ 210MG IRON ^[RLD]

Is there a generic version of Auryxia available?

An Authorized Generic version of Auryxia has been approved. An Authorized Generic is a prescription drug that is produced by a brand company under a New Drug Application (NDA) and marketed as a generic under a private label. It is identical to the branded product in appearance and has exactly the same inactive ingredients.

List of authorized generic versions:

• Ferric Citrate ORAL TABLET, FILM COATED 210 mg
  Mylan Pharmaceuticals Inc.
  NDC Code: 003782895
  

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Auryxia. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: Generic Drug FAQ.

Related patents

Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.

• Ferric citrate dosage forms
  Patent 10,300,039
  Issued: May 28, 2019
  Inventor(s): Le Henry Trong
  Assignee(s): KERYX BIOPHARMACEUTICALS, INC.
  

  Disclosed herein are ferric citrate-containing tablets. In various embodiments, the tablets include ferric citrate formulations that meet certain dissolution, tableting and disintegration standards. In various aspects, the tablet formulations can include ferric citrate as the active ingredient and a binder. The formulations also can include a lubricant and/or a disintegrant (which, in some embodiments, can be the same as the binder).

  Patent expiration dates:

  • July 21, 2030
    
    ✓ 
    Patent use: CONTROL OF SERUM PHOSPHORUS LEVELS
• Pharmaceutical-grade ferric organic compounds, uses thereof and method of making same
  Patent 8,093,423
  Issued: January 10, 2012
  Inventor(s): Chan Keith & Town Winston
  Assignee(s): GloboAsia, LLC
  

  The present invention discloses a pharmaceutical-grade ferric organic compounds, including ferric citrate, which are soluble over a wider range of pH, and which have a large active surface area. A manufacturing and quality control process for making a pharmaceutical-grade ferric citrate that consistently complies with the established Manufacture Release Specification is also disclosed. The pharmaceutical-grade ferric organic compounds are suitable for treating disorders characterized by elevated serum phosphate levels.

  Patent expiration dates:

  • April 21, 2026
    
    ✓ 
    Patent use: CONTROL OF SERUM PHOSPHOROUS LEVELS
• Ferric citrate dosage forms
  Patent 9,387,191
  Issued: July 12, 2016
  Inventor(s): Le Henry Trong
  Assignee(s): Keryx Biopharmaceuticals, Inc.
  

  Disclosed herein are ferric citrate-containing tablets. In various embodiments, the tablets include ferric citrate formulations that meet certain dissolution, tableting and disintegration standards. In various aspects, the tablet formulations can include ferric citrate as the active ingredient and a binder. The formulations also can include a lubricant and/or a disintegrant (which, in some embodiments, can be the same as the binder).

  Patent expiration dates:

  • July 21, 2030
    
    ✓ 
    Drug product

Related/similar drugs

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer